Speakers
Michael De Vivo
Vice President, Neuroscience
BioXcel Therapeutics
Day One
Wednesday 29 September, 2021
1:20 pm | Live Q&A
12:55 pm | BXCL501: Targeting Alpha2-Adrenrgic Receptors for Neuropsychiatric Symptoms
Gary Zammit
President & CEO
Clinilabs Drug Development Corporation
Day One
Wednesday 29 September, 2021
10:50 am | Live Q&A
9:35 am | Trends in Substance Use Disorder Trials
Thomas Insel
Co-founder | Chair
Humanest Care | Steinberg Institute
Day Two
Thursday 30 September, 2021
2:05 pm | Panel Discussion: How Best Can We Drive a Patient Centric Approach to Develop Efficacious & Engaging Digital Therapeutics?
Massimiliano Bianchi
Founder / President & CEO
Ulysses Neuroscience
Day One
Wednesday 29 September, 2021
12:40 pm | Translational Research in Neuropsychiatry: An Update From Ulysses Neuroscience Ltd.
1:20 pm | Live Q&A
John Kealy
CSO
Ulysses Neuroscience
Day Two
Thursday 30 September, 2021
9:10 am | Panel Discussion: Exploring Novel Electrophysiological Biomarkers of Synaptic Plasticity in Humans
Daniel Mathalon
Professor of Psychiatry and Behavioral Sciences
UCSF Weill Institute for Neurosciences
Day Two
Thursday 30 September, 2021
9:10 am | Panel Discussion: Exploring Novel Electrophysiological Biomarkers of Synaptic Plasticity in Humans
Robert Goldel
Neuroscientist & Technologist
Day Two
Thursday 30 September, 2021
2:05 pm | Panel Discussion: How Best Can We Drive a Patient Centric Approach to Develop Efficacious & Engaging Digital Therapeutics?
Jonathan Nassi
Senior Director Translational Science
Inscopix
Jonathan joined Inscopix in 2015. He received his PhD in Neuroscience from UCSD and did postdoctoral fellowships at Harvard Medical School and the Salk Institute. Jonathan is an experienced systems neurobiologist with research interests spanning neuroanatomy, in-vivo imaging, electrophysiology, optogenetics and behavioral measurements to study neural circuit function in rodents and non-human primates. At Inscopix, Jonathan oversees our translational science programs and works toward the advancement of innovative technologies that will enable tomorrow's breakthrough neuroscience discoveries and next-generation therapies for neurodegenerative and neuropsychiatric disease
Day Two
Thursday 30 September, 2021
10:35 am | A neural circuits platform to accelerate and de-risk preclinical neuropsychiatric drug development
10:50 am | Live Q&A
Jonathan Rogers
Wellcome Trust Clinical Training Fellow
UCL Division of Psychiatry
Day Two
Thursday 30 September, 2021
3:05 pm | Neuropsychiatric Implications of COVID 19
5:45 pm | Live Q&A
Judy Ashworth
Vice President Rx Strategic Services & Chief Medical Officer
Pinney Associates
Day One
Wednesday 29 September, 2021
3:25 pm | Clinical & Regulatory Challenges in Developing Psychedelics as Therapeutics
3:40 pm | Live Q&A
Judith Ford
Co-Director, Brain Imaging & EEG Lab, Professor, Department of Psychiatry, UCSF;
Senior Research Career Scientist San Francisco Veterans Affairs Medical Center
Day Two
Thursday 30 September, 2021
10:10 am | Thalamo-cortical Dysconnectivity in Schizophrenia & Youth a High Clinical Risk for Schizophrenia
Benedicto Crespo-Facorro
Director UGC HU Virgen del Rocío
CIBERSAM, Catedrático de Psiquiatría, Universidad de Sevilla
Day Two
Thursday 30 September, 2021
5:20 pm | Pharmacotranscriptomic Profiling & Molecular Mechanisms Triggered by Antipsychotics: Boosting the Search of New Drug Targets in Schizophrenia
5:45 pm | Live Q&A
Terence Kelly
CEO
Perception Neuroscience
Day One
Wednesday 29 September, 2021
10:25 am | 1PCN-101 (R-ketamine) for Treatment Resistance Depression
10:50 am | Live Q&A
Mark Varney
Chief Scientific Officer
PsychoGenics
Day One
Wednesday 29 September, 2021
5:10 pm | Live Q&A
4:30 pm | AI-driven Phenotypic Drug Discovery for CNS Indications
Stephen J. Ferrando
Director of Psychiatry at Westchester Medical Center (WMC)
Chairman of Psychiatry at New York Medical College
Day Two
Thursday 30 September, 2021
3:05 pm | Neuropsychiatric Implications of COVID 19
5:45 pm | Live Q&A
John Renger
Ph.D, Chief Scientific Officer
Cerevel Therepeutics
Day One
Wednesday 29 September, 2021
10:00 am | Development of CVL-231 for the Treatment of Psychosis
10:50 am | Live Q&A
Srinivas Rao
Co-Founder & Chief Scientific Officer
Atai Life Sciences
Day One
Wednesday 29 September, 2021
3:40 pm | Live Q&A
2:35 pm | Exploring Atai’s Unique Strategy: A Model for Innovation & Growth
Heather Dworak
Senior Director, Clinical Research
Sunovion
Day One
Wednesday 29 September, 2021
1:20 pm | Live Q&A
11:50 am | Development of SEP-363856, a TAAR1/5-HT1A Agonist for the Treatment of Schizophrenia
Amy Peters
Instructor, Department of Psychiatry Massachusetts
General Hospital & Harvard Medical School
Day Two
Thursday 30 September, 2021
5:45 pm | Live Q&A
4:05 pm | Inflammatory Mechanisms of Cognitive Dysfunction in Bipolar Disorder
Pradeep Nathan
Vice President & Head of Experimental Medicine & Professor of Neuroscience
Lundbeck
Day Two
Thursday 30 September, 2021
10:50 am | Live Q&A
9:10 am | Panel Discussion: Exploring Novel Electrophysiological Biomarkers of Synaptic Plasticity in Humans
Isabella Premoli
Imaging & Neurostimulation Specialist,
Lundbeck
Day Two
Thursday 30 September, 2021
12:50 pm | Live Q&A
12:00 pm | Implementation of a Multi-Modal Brain Stimulation Approach in Early Stage Clinical Trials
Jessica Malberg
Director, Neuroscience Development
INmune Bio
Day Two
Thursday 30 September, 2021
5:45 pm | Live Q&A
4:55 pm | TNF Inhibition as Treatment for Treatment-Resistant Depression
Daniel R Karlin
CMO,
MindMed
Day Two
Thursday 30 September, 2021
2:05 pm | Panel Discussion: How Best Can We Drive a Patient Centric Approach to Develop Efficacious & Engaging Digital Therapeutics?
Kurt Rasmussen
CSO
Delix Therapeutics
Day One
Wednesday 29 September, 2021
10:50 am | Live Q&A
9:10 am | Substance Use Disorders as a Lifecycle Play for Neuropsychiatric Drugs
Rick Doblin
Executive Director
Multidisciplinary Association for Psychedelic Studies
Day One
Wednesday 29 September, 2021
3:40 pm | Live Q&A
3:00 pm | MDMA-Assisted Therapy: With One Successful Phase 3 Study, Is FDA Approval on the Horizon?
Anindya Bhattacharya
Senior Director, Head Neuroimmunology, Neuroscience Therapeutic Area
Janssen Pharmaceutical Companies of Johnson & Johnson
Day Two
Thursday 30 September, 2021
5:45 pm | Live Q&A
4:30 pm | Dysregulated NeuroImmune Axes in Mood Disorders
Xiohai Wang
Director, Neuroscience
Merck
Day One
Wednesday 29 September, 2021
1:20 pm | Live Q&A
12:15 pm | Translational Pharmacology & Biomarker Development of the Novel α7 nAChR Positive Allosteric Modulator BNC375
Daniel C. Javitt
Director, Schizophrenia Research Program, Nathan S.Kline Institute for Psychiatric Research
Professor & Director, Division of Experimental Therapeutics, Columbia University College
Day Two
Thursday 30 September, 2021
12:50 pm | Live Q&A
11:35 am | Investigating Sensory ERP Biomarkers for Disease & Target Engagement
Jackie von Salm
Co-Founder, CSO
Psilera Bioscience
Day One
Wednesday 29 September, 2021
5:10 pm | Live Q&A
4:45 pm | Translational Research to Raise the Bar for the Development of Psychedelic-Based Medicines
Patricio O’Donnell
Executive Medical Director, Head of Neurocircuitry Modulation Biomarkers
Takeda
Day Two
Thursday 30 September, 2021